They followed 73,483 adults taking GLP-1sincluding semaglutide drugs like Ozempic and Wegovy, as well as Victoza (liraglutide), Trulicity (dulaglutide), or Byetta (exenatide)and compared them with the same number of adults not taking the medications, tracking health outcomes for five years after treatment began
Daeppen, Lausanne (Mdecine des addictions)
Hayes MR, Skibicka KP, Leichner TM, Guarnieri DJ, DiLeone RJ, Bence KK et al (2010b)
While both medications can be effective, theyve also been notoriously expensive, especially if you don't have insurance coverage
The medications boost residue rates across the board
Janeczko, MPH Cardiology | July 24, 2026 Explore how the Cardiovascular-Kidney-Metabolic framework changes risk assessment and multisystem management strategies